Healthcare provider profile · identity verified

Steven M Witzel, MD

Internal Medicine · VERNON HILLS, IL · NPI 1922064641

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	367	128
Amlodipine Besylate	Amlodipine Besylate	240	87
Lisinopril	Lisinopril	190	68
Hydrochlorothiazide	Hydrochlorothiazide	174	64
Levothyroxine Sodium	Levothyroxine Sodium	152	56
Metoprolol Succinate	Metoprolol Succinate	141	47
Pantoprazole Sodium	Pantoprazole Sodium	141	54
Gabapentin	Gabapentin	128	43
Metformin Hcl	Metformin Hcl	118	43
Tamsulosin Hcl	Tamsulosin Hcl	103	38
Omeprazole	Omeprazole	100	33
Losartan Potassium	Losartan Potassium	88	34
Rosuvastatin Calcium	Rosuvastatin Calcium	75	32
Alprazolam	Alprazolam	71	15
Simvastatin	Simvastatin	71	27
Valsartan	Valsartan	64	19
Eliquis	Apixaban	55	16
Sertraline Hcl	Sertraline Hcl	51	20
Pravastatin Sodium	Pravastatin Sodium	47	17
Albuterol Sulfate Hfa	Albuterol Sulfate	43	18
Montelukast Sodium	Montelukast Sodium	40	14
Donepezil Hcl	Donepezil Hcl	38	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	38	14
Metoprolol Tartrate	Metoprolol Tartrate	38	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	12
Clonazepam	Clonazepam	35	suppressed
Meloxicam	Meloxicam	35	15
Buspirone Hcl	Buspirone Hcl	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Furosemide	Furosemide	33	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Trazodone Hcl	Trazodone Hcl	33	17
Carvedilol	Carvedilol	32	14
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Tramadol Hcl	Tramadol Hcl	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Celecoxib	Celecoxib	29	13
Allopurinol	Allopurinol	28	11
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Glimepiride	Glimepiride	26	11
Breo Ellipta	Fluticasone/Vilanterol	25	suppressed
Potassium Chloride	Potassium Chloride	25	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Ozempic	Semaglutide	21	suppressed
Telmisartan	Telmisartan	21	suppressed
Ketoconazole	Ketoconazole	20	11
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Lorazepam	Lorazepam	18	suppressed
Temazepam	Temazepam	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Febuxostat	Febuxostat	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	14	suppressed
Glipizide	Glipizide	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Finasteride	Finasteride	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Zaleplon	Zaleplon	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error